Studies have shown that clusterin (also called apolipoprotein J) can influence the structure and toxicity of amyloid-␤ (A␤) in vitro. To determine whether endogenous clusterin plays a role in influencing A␤ deposition, structure, and toxicity in vivo, we bred PDAPP mice, a transgenic mouse model of Alzheimer's disease, to clusterin ؊/؊ mice. By 12 months of age, PDAPP, clusterin ؊/؊ mice had similar levels of brain A␤ deposition as did PDAPP, clusterin ؉/؉ mice. Although A␤ deposition was similar, PDAPP, clusterin ؊/؊ mice had significantly fewer fibrillar A␤ (amyloid) deposits than PDAPP mice expressing clusterin. In the absence of clusterin, neuritic dystrophy associated with the deposited amyloid was markedly reduced, resulting in a dissociation between fibrillar amyloid formation and neuritic dystrophy. These findings demonstrate that clusterin markedly influences A␤ structure and neuritic toxicity in vivo and is likely to play an important role in Alzheimer's disease pathogenesis.
Studies have shown that clusterin (also called apolipoprotein J) can influence the structure and toxicity of amyloid-␤ (A␤) in vitro. To determine whether endogenous clusterin plays a role in influencing A␤ deposition, structure, and toxicity in vivo, we bred PDAPP mice, a transgenic mouse model of Alzheimer's disease, to clusterin ؊/؊ mice. By 12 months of age, PDAPP, clusterin ؊/؊ mice had similar levels of brain A␤ deposition as did PDAPP, clusterin ؉/؉ mice. Although A␤ deposition was similar, PDAPP, clusterin ؊/؊ mice had significantly fewer fibrillar A␤ (amyloid) deposits than PDAPP mice expressing clusterin. In the absence of clusterin, neuritic dystrophy associated with the deposited amyloid was markedly reduced, resulting in a dissociation between fibrillar amyloid formation and neuritic dystrophy. These findings demonstrate that clusterin markedly influences A␤ structure and neuritic toxicity in vivo and is likely to play an important role in Alzheimer's disease pathogenesis.
A myloid-␤ (A␤) peptides are predominantly 39-43 aa in length and are derived from the amyloid precursor protein (APP) through endoproteolytic cleavage. Abundant evidence suggests that the conversion of A␤ from soluble to insoluble forms in the brain is a key event in the pathogenesis of Alzheimer's disease (AD). Genetic and biochemical evidence supporting this idea is that all known mutations that cause early-onset forms of familial AD or 〈␤-related cerebral amyloid angiopathy map to three genes [APP, presenilin-1 (PS-1), and PS-2] (1, 2). Most of these mutations result in relative overproduction of A␤ 42 , a particularly amyloidogenic form of A␤, which over time increases the probability of A␤ aggregation. Some mutations in APP within the A␤-coding region that result in familial cerebral amyloid angiopathy do not seem to increase A␤ production but increase its propensity for aggregation and toxicity (3, 4) . Although these mutations have given insight into a central role for A␤ in both AD and cerebral amyloid angiopathy, cases of ''sporadic,'' late-onset AD (age Ͼ60 years), which accounts for most AD cases, are not associated with increased A␤ production or altered A␤ sequence.
The probability that A␤ will aggregate into different insoluble forms in the brain can be influenced by A␤-binding proteins, a process which occurs after A␤ generation. One example of a protein that seems to influence A␤ in this way is apolipoprotein E (apoE). The apoE4 isoform of apoE is the only proven genetic risk factor for both late-onset AD and cerebral amyloid angiopathy, and studies suggest that apoE influences A␤ structure, clearance, and neuritic toxicity both in vitro and in vivo with no clear effect on A␤ production (5-7). Whether apolipoproteins other than apoE influence A␤ aggregation and toxicity in vivo is unknown, although a good candidate for such effects is apolipoprotein J, also known as clusterin.
The two most abundantly expressed apolipoproteins in the central nervous system that are present at similar concentrations are apoE and clusterin (8) (9) (10) (11) (12) . Both apoE and clusterin are expressed by glia and are present in predominantly distinct high-density lipoproteins (13, 14) . Studies have shown that clusterin is present in plaques (15, 16) , up-regulated in the AD brain (15) , associated with soluble A␤ in cerebrospinal fluid (17) , and can facilitate A␤ transport across the blood-brain barrier (18, 19) . In vitro studies have shown that purified clusterin can interact with A␤ (20) and influence fibril formation (21, 22) as well as acute A␤ neurotoxicity (21, 23, 24) . Although these studies suggest that clusterin-A␤ interactions may be relevant to AD, whether clusterin plays a direct role in the formation of AD pathology in vivo is not clear.
To evaluate further the role of clusterin in AD pathology, we bred PDAPP mice, a transgenic mouse model that develops AD-like neuropathology to clusterin
mice. Our findings demonstrate that clusterin expression facilitates but is not required for A␤ fibril (amyloid) formation. In addition, amyloid deposits that form in the absence of clusterin expression are associated with far fewer dystrophic neurites. Despite similar levels of A␤ accumulation in the brain, the absence of clusterin was also associated with alterations in the levels of soluble brain A␤. Together, these studies suggest a role for clusterin in influencing amyloid deposition and the associated neuritic toxicity in vivo.
Methods and Materials
Animals and Tissue Preparation. PDAPP mice, homozygous (ϩ/ϩ) for the APP V717F transgene (25, 26) , were bred to clusterin knockout mice (27, 28) to yield PDAPP ϩ/Ϫ , clusterin ϩ/Ϫ progeny. The progeny were then bred to each other and animals that were PDAPP ϩ/ϩ , clusterin . Tissue analysis was performed exactly as described (29) . Animals were analyzed at 3, 6, 9, 12, and 15 months of age.
Histological Analysis. Tissue sections were cut in the coronal plane at 40 m on a freezing sliding microtome from the genu of the corpus callosum through the caudal extent of the hippocampus. The percent surface area covered by A␤-immunoreactive deposits (% A␤ Load) as identified with a rabbit pan-A␤ antibody This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: A␤, amyloid-␤; APP, amyloid precursor protein; AD, Alzheimer's disease; apoE, apolipoprotein E.
(BioSource International, Camarillo, CA) was quantified according to stereological principles as described (30) . Thioflavine-S staining was performed as described (26) . A␤ and thioflavine-S load were determined in the cingulate cortex and hippocampus in three sections, each separated by 300 m. The de Olmos silver stain was performed as described (31) , and the number of dystrophic neurites present in three sections determined.
A␤ Quantification. A␤ Total and A␤ 42 levels in guanidine lysates were assayed as described (32) . In brief, hippocampal or cortical tissue was homogenized in a denaturing buffer containing 5 M guanidine plus protease inhibitors. The extracts were diluted and analyzed in denaturing ELISAs containing a final concentration of 500 mM guanidine for A␤ Total (m266 as capture antibody and biotinylated m3D6 as reporter antibody) or A␤ 42 (m21F12 as capture antibody and biotinylated m3D6 as reporter antibody). To evaluate the potential soluble pools of brain A␤, we also performed a carbonate extraction (100 mM carbonate͞50 mM NaCl/protease inhibitors, pH 11.5) of hippocampal and cortical tissue (1:20, wt͞vol) on ice. Tissue samples were Dounce homogenized and spun in a microcentrifuge at 14,000 rpm for 15 min at 4°C. The supernatant was placed in a fresh tube on ice and the pH of the lysate was neutralized to 7.4 with 1 M Tris (pH 6.8).
The carbonate soluble pool of A␤ Total was determined with denaturing (described above) and nondenaturing (lacking guanidine) ELISAs. An additional A␤ ELISA was developed to identify possible oligomeric species of A␤. A monoclonal antibody directed against the first five residues of human A␤ was used for both capturing (m3D6) and detecting (biotinylated m3D6) A␤.
Acid Gels. We modified our denaturing polyacrylamide gel system (33) to identify individual A␤ peptides present in the tissue lysates. The carbonate-soluble extract was denatured in formic acid (final concentration, 70%) and reduced with ␤-mercaptoethanol (1%). The denatured extracts were run (anode to cathode) in a 1 M acetic acid buffer through a 1.6 M acetic acid͞6 M urea step gel of the following polyacrylamide percentages: 4% stacker (2.5% N,N,NЈ,NЈ-tetramethylethylenediamine), 10% step (2.5% N,N,NЈ,NЈ-tetramethylethylenediamine), and a 22% resolving gel (1 
.875% N,N,NЈ,NЈ-tetramethylethylenediamine).
The acidic pH of the gel was neutralized before transfer to nitrocellulose. Standard Western blotting procedures were then performed as described (33) .
Statistical Analysis. All statistical analysis was performed by using PRISM V.3.00 (GraphPad, San Diego) for WINDOWS (Microsoft).
Results
To determine whether clusterin influenced the age of onset or amount of A␤ deposition in PDAPP We next asked whether clusterin influenced the anatomical distribution of A␤ deposits and the A␤ structure itself. The anatomical distribution of A␤ deposition in clusterin ϩ/ϩ and clusterin Ϫ/Ϫ mice was similar in general, although subtle differences seemed to exist (Fig. 2 A and B) . A␤ deposits were prominent in the hippocampus, especially within the molecular layer of the dentate gyrus in the presence or absence of clusterin. In addition, A␤ immunoreactivity was prominent in the cingulate cortex of both groups. A␤ immunoreactivity was, however, more diffuse in appearance in the absence of clusterin with fewer ''compact'' plaques ( Fig. 2 A) . In contrast to the pattern of A␤ immunoreactivity, marked differences occurred between the groups in the absolute amount and area occupied (percent load) of thioflavine-S-positive A␤ deposits (amyloid) by 12 months of age. Although 77% (10 of 13) clusterin Fig. 2 A) . In addition to promoting cortical amyloid deposition, clusterin also promoted the formation of hippocampal amyloid (Fig. 2 A) . Although all PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ mice (n ϭ 15) analyzed at 12 months had thioflavine-S-positive deposits in the hippocampus, these mice had significantly less hippocampal amyloid burden (0.89 vs. 2.76% thioflavine load, P ϭ 0.05), as well as a decrease in the percent of A␤-immunoreactive deposits that were thioflavine-S-positive (2.46 vs. 19.4% thioflavine load͞A␤ load, P Ͻ 0.0001; Fig. 2 mice (data not shown). Thus, as for apoE (26, 29, 30, 35) , clusterin facilitates the conversion of A␤ to fibrillar forms in vivo.
In APP transgenic mice and in human AD, thioflavine-Spositive deposits of fibrillar A␤ (amyloid) are surrounded by enlarged, distorted dendrites and axons (neuritic plaques͞ dystrophy; refs. 30 and 36), which suggests that the amyloid fibrils themselves (or some form of A␤ associated with amyloid mice by using both thioflavine-S and the de Olmos silver stain. As we have shown in PDAPP mice (30) , all thioflavine-S-positive deposits in PDAPP ϩ/ϩ , clusterin ϩ/ϩ mice were surrounded by multiple enlarged, dystrophic neurites (Fig. 3A) . Although fewer thioflavine-S-positive deposits occurred in the absence of clusterin (see above), amyloid deposition was readily demonstrated. The neuritic dystrophy surrounding amyloid deposits in PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ mice, however, was markedly reduced with many deposits having few to no detectable dystrophic neurites (Fig. 3A) . Quantitatively, a 10-fold reduction occurred in dystrophic neurites in the hippocampus of PDAPP (Fig. 3B) , and a 5-fold reduction in the number of dystrophic neurites per amyloid deposit (Fig. 3B) . We also assessed PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ mice at 15 months of age. Thioflavine-S-positive amyloid load in the hippocampus increased from 0.89% at 12 months to 2.25 Ϯ 0.48% (mean Ϯ SEM, n ϭ 8) at 15 months. Despite this increase, the number of dystrophic neurites per amyloid deposit did not increase from 12 months (42.9 Ϯ 13.8, n ϭ 15) to 15 months (35.7 Ϯ 19.4, n ϭ 8). Thus, although clusterin promotes amyloid formation, it also facilitates the neuritic toxicity associated with the amyloid formed in its presence.
The dissociation between amyloid formation and neuritic dystrophy in PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ mice suggested that clusterin might be influencing a soluble ''toxic'' species͞form of A␤ during or after the process of A␤ deposition. To address this possibility, we assessed the amount of carbonate-soluble brain A␤ by ELISA in cortical brain homogenates under both denaturing and nondenaturing conditions. By using an ELISA for A␤ Total under denaturing conditions, the levels of carbonatesoluble A␤ in brain lysates of PDAPP mice with A␤ deposition, levels of carbonate-soluble A␤ increased by 5-to 10-fold and no significant difference between genotypes was observed, even when the values were normalized to the percent A␤ load (Fig. 4A) . Normalization of the data were required because of the extreme variability in A␤ deposition coupled to an observed highly significant correlation between levels of deposited and soluble A␤. However, when performing the same ELISA under nondenaturing conditions, we observed that the amount of A␤ Total ͞% A␤ load was significantly higher in the presence vs. the absence of clusterin (0.94 vs. 0.39, P ϭ 0.0111; Fig. 4B ). A similar trend was observed in the nondepositing animals (data not shown). The amount of A␤ Total detected by nondenaturing ELISA was 2-to 3-fold lower than that observed under denaturing conditions, which suggests that an appreciable fraction of soluble A␤ may be present in different conformations, such as small oligomeric forms, leading to antigenic masking under certain conditions. To assess this issue further, we used the same N-terminal monoclonal anti-A␤ antibody (3D6) to both capture and detect A␤ in our sandwich ELISA. This format should only detect A␤ present in oligomeric forms. By using this assay on carbonate-soluble homogenates under nondenaturing conditions, we observed that the levels of A␤ present were very similar to those found in the same lysates when assayed under denaturing conditions (which disrupt oligomer formation). No statistical difference existed in the amount of A␤ in the presence or absence of clusterin in this assay, which suggests that mice detected under nondenaturing conditions may be monomeric. To determine whether differences existed in the species of soluble brain A␤ in the presence or absence of clusterin in plaque-bearing mice, we ran soluble brain lysates in completely denaturing acid-urea gels followed by Western blotting for A␤. We found that most soluble brain A␤ in clusterin ϩ/ϩ and clusterin Ϫ/Ϫ mice was A␤ 42 (Fig. 5) . A small amount of A␤ 40 and lower molecular weight A␤ species were also detected in all clusterin ϩ/ϩ mice analyzed in this fashion (n ϭ 4); however, A␤ 40 was not detected in the soluble brain homogenates of the clusterin Ϫ/Ϫ mice assayed (n ϭ 4). Taken together, the data suggest that clusterin is influencing not only the form but also the species of A␤ associated with the soluble brain fraction.
Discussion
We have developed and characterized PDAPP ϩ/ϩ transgenic animals that were either clusterin-expressing or -deficient to test whether clusterin plays any role in vivo in the cascade of amyloid deposition and toxicity. Although clusterin did not have a significant effect on the absolute levels of deposited brain A␤ at 12 months of age, its presence was associated with increased fibril formation. Moreover, we observed that the thioflavine-Spositive amyloid that deposits in the absence of clusterin is associated with far less neuritic dystrophy than amyloid present in clusterin-expressing PDAPP mice. Although the brain of clusterin Ϫ/Ϫ mice seems to develop and age normally, it is possible that the absence of clusterin results in a compensatory change in other molecules that results in the phenotype we observed. However, our data combined with prior in vitro data suggest that clusterin is directly involved in A␤ metabolism in vivo. It was found that purified clusterin can bind to soluble A␤ 40 with a dissociation constant characteristic of a high-affinity interaction (K d of 2 nM) (20) . In addition, multiple laboratories have shown that clusterin prevents aggregation and polymerization of synthetic A␤ in vitro (21, 22) . Other studies have shown that clusterin may be an important regulator of soluble central nervous system A␤ levels. Studies by Zlokovic and colleagues have shown that A␤-clusterin complexes can be transported across the blood-brain barrier by a high-affinity receptormediated process involving transcytosis (18, 19) . In addition, cell culture experiments have demonstrated that A␤ uptake and degradation is facilitated by the presence of clusterin (37) . Although these in vitro studies highlight possible physiologically relevant interactions between clusterin and A␤, it was unknown whether clusterin had any role in the process of amyloidogenesis in vivo.
We demonstrate that expression of murine clusterin in some way facilitates the conversion of a larger percentage of aggregated A␤ into thioflavine-S-positive amyloid as compared with clusterin-deficient mice. Some in vitro studies have demonstrated that at certain concentrations, purified clusterin can interact with A␤ and result in an inhibition of fibril formation (21, 22) . Although these results may seem contradictory to our in vivo findings, it is always difficult to know a priori whether observations obtained from a two-component, cell-free in vitro assay will be the same as those found in the complex in vivo situation. Many factors (multiple binding proteins, proteolytic events, and clear- ance mechanisms) function in vivo, complicating interpretation͞ extrapolation of in vitro findings. We have also identified a highly significant dissociation between amyloid (fibrillar A␤) and neuritic toxicity in PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ mice. Even after normalizing for the amount of amyloid plaque (thioflavine-Spositive A␤ deposits) in the clusterin-deficient mice, a 5-fold decrease occurred in the number of dystrophic neurites. The mechanism underlying the increased neuritic toxicity we observed in clusterin-expressing PDAPP mice is unclear. One possibility is that the thioflavine-S-positive amyloid formed in the presence vs. the absence of clusterin is structurally different. Another possibility is that clusterin is promoting the formation of toxic soluble oligomeric forms of A␤ (21, 24, 38, 39) . Oda et al. , for example, demonstrated that clusterin decreased aggregation of A␤ 42 and that subsequent incubation of the less aggregated material to PC12 cells significantly increased oxidative stress (21) . Studies by Lambert et al. showed that small diffusible oligomers of A␤ 42 induced by the presence of clusterin were associated with increased neuronal toxicity in organotypic central nervous system cultures at nanomolar concentrations (24) . In addition, soluble oligomers of A␤ 42 were found to be deleterious for long-term potentiation in the dentate gyrus of rat hippocampal slices (39) , and protofibrillar intermediates of A␤ induced acute electrophysiological and toxic changes to cortical neurons (40) .
A systematic biochemical examination of carbonate-soluble brain extracts with a nondenaturing ELISA that should be specific for oligomeric forms of A␤ in carbonate-soluble lysates detected no significant differences between PDAPP ϩ/ϩ , clusterin ϩ/ϩ and clusterin Ϫ/Ϫ mice. However, by using A␤ ELISAs under both denaturing and nondenaturing conditions, we did identify a significant 2-fold increase in the pool of A␤ which may be monomeric in mice expressing clusterin. Whether an A␤ monomeric pool was present in the oligomeric A␤ populations used in some previous in vitro studies (21, 24, 38, 39) is unknown.
Analysis of carbonate-soluble brain extracts by acid-urea gels revealed the presence of several A␤ peptides, with A␤ 42 being the predominant form present irrespective of clusterin genotype. We noted the complete absence of human A␤ 40 in the soluble lysates from PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ mice. Although the exact meaning of this clusterin-dependent alteration of soluble A␤ is unknown, these data are further direct evidence that clusterin modifies A␤ metabolism and͞or structure to influence amyloid deposition.
How might the clusterin-dependent dissociation between fibrillar amyloid and neuritic toxicity relate to the observed differences in the concentrations of soluble pools A␤ that we detected? The answer may lie in an emerging literature documenting the role of clusterin as a secreted chaperone protein (41) (42) (43) (44) . Several recent studies have shown that clusterin can ''solubilize'' a very broad spectrum of proteins that contain exposed hydrophobic patches (41, 42) . This chaperone-like activity has been attributed to a molten globule-like region located in the clusterin protein itself (43, 44) . It is possible that the chaperone-like properties of clusterin may be inducing local alterations in the equilibrium between deposited and soluble monomeric A␤ and, as a consequence, unmask toxic epitopes present in either fibrillar amyloid or soluble A␤, thereby increasing neuritic toxicity and facilitating further expansion of the fibrillar amyloid. Our results demonstrate that clusterin is a critical component in vivo for the development of amyloid as well as its associated neuritic toxicity. The data also suggest that modifying clusterin expression is likely to have important effects on AD pathology and that further study of the mechanism underlying these clusterin-mediated effects on A␤ structure and toxicity may yield important insights for therapeutic intervention.
We thank Eric Foss and Malca Kierson for their technical assistance and Barbara Cordell and Patrick May for helpful comments. We also acknowledge the support of Eli Lilly and Scios, Inc. This work was supported by National Institutes of Health Grants AG05681, AG13956, and AG11355 (to D.M.H.). Clusterin expression alters the soluble pool of brain A␤. (A) Carbonate-soluble hippocampal extracts from 12-month-old PDAPP ϩ/ϩ , clusterin ϩ/ϩ (n ϭ 13) and PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ (n ϭ 15) mice had similar levels of A␤ Total when assayed by ELISA under denaturing conditions. The A␤ Total concentrations (nanograms per milligram of protein) were normalized to the percent A␤ load to correct for the variability in deposition between animals. (B) When the carbonate extracts were analyzed under nondenaturing conditions with the same ELISA, mice expressing clusterin had a significant 2-fold increase in the soluble pool of A␤ Total. * , P ϭ 0.01.
(C) Carbonate extracts analyzed under nondenaturing conditions with an ELISA by using the same capture and detecting antibody (resulting in an assay that should be specific for oligomeric forms of A␤) did not detect a significant difference between PDAPP ϩ/ϩ , clusterin ϩ/ϩ and PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ mice. Data in B and C are means Ϯ SEM.
Fig. 5.
The subtle difference in the A␤ peptide composition of the soluble pool of brain A␤ is revealed by acid-urea polyacrylamide gels. The A␤ peptide composition of the carbonate-soluble hippocampal extracts from 12-month-old PDAPP ϩ/ϩ , clusterin ϩ/ϩ and PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ mice was determined by acid-urea gel analysis (n ϭ 4 per group). Human A␤ 40 and A␤42 synthetic peptides are used for mass and migration comparisons. Soluble extracts analyzed under the completely denaturing conditions demonstrate that human A␤ 42 is the predominant A␤ peptide present. Human A␤ 40 was readily detectable in extracts from all PDAPP ϩ/ϩ , clusterin ϩ/ϩ mice examined, whereas human A␤40 could not be detected in PDAPP ϩ/ϩ , clusterin Ϫ/Ϫ extracts.
